Dependence of cardiac11C-meta-hydroxyephedrine retention on norepinephrine transporter density

Journal of Nuclear Medicine

Volumn 47, Issue 9, 2006, Pages 1490-1496

  Raffel, David M ^a   Chen, Wei ^a   Sherman, Phillip S ^a   Gildersleeve, David L ^a   Jung, Yong Woon ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

6 hydroxydopamine; Meta hydroxyephedrine; Norepinephrine transporter; PET; Sympathetic nervous system

Indexed keywords

3 HYDROXYEPHEDRINE; 3 HYDROXYEPHEDRINE C 11; MAZINDOL; NORADRENALIN TRANSPORTER; OXIDOPAMINE; RADIOPHARMACEUTICAL AGENT; TRITIUM; UNCLASSIFIED DRUG; 3-HYDROXYEPHEDRINE; CARBON; DIAGNOSTIC AGENT; DRUG DERIVATIVE; EPHEDRINE; SLC6A2 PROTEIN, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING ASSAY; BINDING SITE; CENTRIFUGATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DENSITY; DRUG BLOOD LEVEL; DRUG RETENTION; DRUG TISSUE LEVEL; DRUG UPTAKE; HEART; HEART DENERVATION; HEART INNERVATION; HEART NERVE; HEART SCINTISCANNING; MALE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; SPRAGUE DAWLEY RAT; SYMPATHETIC INNERVATION; SYMPATHETIC NERVE; TISSUE HOMOGENATE; ADRENERGIC SYSTEM; ANIMAL; HEART MUSCLE; INNERVATION; METABOLIC CLEARANCE RATE; METABOLISM; SCINTISCANNING; TISSUE DISTRIBUTION;

ANIMALS; CARBON RADIOISOTOPES; EPHEDRINE; HEART; MALE; METABOLIC CLEARANCE RATE; MYOCARDIUM; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; SYMPATHETIC NERVOUS SYSTEM; TISSUE DISTRIBUTION;

EID: 33750583619     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Rosenspire KC, Haka MS, Van Dort ME, et al. Synthesis and preliminary evaluation of carbon-11-meta-hydroxyephedrine: a false transmitter agent for heart neuronal imaging. J Nucl Med. 1990;31:1328-1334.
2. Iversen LL. The uptake of catechol amines at high perfusion concentrations in the rat isolated heart: a novel catechol amine uptake process. Br J Pharmacol. 1965;25:18-33.
3. Hartmann F, Ziegler S, Nekolla S, et al. Regional patterns of myocardial sympathetic denervation in dilated cardiomyopathy: an analysis using carbon-11 hydroxyephedrine and positron emission tomography. Heart. 1999;81:262-270.
4. Pietilä M, Malminiemi K, Ukkonen H, et al. Reduced myocardial carbon-11 hydroxyephedrine retention is associated with poor prognosis in chronic heart failure. Eur J Nucl Med. 2001;28:373-376.
5. Bengel FM, Permanetter B, Ungerer M, Nekolla S, Schwaiger M. Alterations of the sympathetic nervous system and metabolic performance of the cardiomyopathic heart. Eur J Nucl Med Mol Imaging. 2002;29:198-202.
6. Allman KC, Stevens MJ, Wieland DM, Wolfe ER, Greene DA, Schwaiger M. Noninvasive assessment of cardiac diabetic neuropathy by C-11 hydroxyephedrine and positron emission tomography. J Am Coll Cardiol. 1993;22:1425-1432.
7. Stevens MJ, Raffel DM, Allman KC, et al. Cardiac sympathetic dysinnervation in diabetes: an assessment by C-11 hydroxyephedrine and positron emission tomography. Circulation. 1998;98:961-968.
8. Stevens MJ, Raffel DM, Allman KC, Schwaiger M, Wieland DM. Regression and progression of cardiac sympathetic dysinnervation complicating diabetes: an assessment by C-11 hydroxyephedrine and positron emission tomography. Metabolism. 1999;48:92-101.
9. Allman KC, Wieland DM, Muzik O, Degrado TR, Wolfe ER, Schwaiger M. Carbon-11 hydroxyephedrine with positron emission tomography for serial assessment of cardiac adrenergic neuronal function after acute myocardial infarction in humans. J Am Coll Cardiol. 1993;22:368-375.
10. Calkins H, Lehmann M, Allman K, Schwaiger M. Scintigraphic pattern of regional cardiac sympathetic innervation in patients with familial long QT syndrome using positron emission tomography. Circulation. 1993;87:1616-1621.
11. 11C-hydroxyephedrine in genotyped long QT patients: a potential amplifier role for severity of the disease. Am J Physiol Heart Circ Physiol. 2003;285:H1286-H1293.
12. Thoenen H, Tranzer JP. Chemical sympathectomy by selective destruction of adrenergic nerve endings with 6-hydroxydopamine. Naunyn Schmiedebergs Arch Pharmacol. 1968;261:271-288.
13. 11C]-methyl triflate. Appl Radiat Isot. 1992;43:1383-1385.
14. National Research Council. Guide for the Care and Use of Laboratory Animals. Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health; 1985.
15. 3H]mazindol to cardiac norepinephrine transporters: kinetic and equilibrium studies. Naunyn Schmiedebergs Arch Pharmacol. 2004;370:9-16.
16. De Champlain J. Degeneration and regrowth of adrenergic nerve fibers in the rat peripheral tissues after 6-hydroxydopamine. Can J Physiol Pharmacol. 1971;49:345-355.
17. Kostrzewa RM, Jacobowitz DM. Pharmacological actions of 6-hydroxydopamine. Pharmacol Rev. 1974;26:199-288.
18. Raffel DM, Wieland DM. Assessment of cardiac sympathetic nerve integrity with positron emission tomography. Nucl Med Biol. 2001;28:541-559.
19. Kemmerer ES, Desmond TJ, Albin RL, Kilbourn MR, Frey KA. Treatment effects on nigrostriatal projection integrity in partial 6-OHDA lesions: comparison of L-DOPA and pramipexole. Exp Neurol. 2003;183:81-86.
20. 11C]-m-hydroxyephedrine in the rat. Nucl Med Biol. 1997;24:417-424.
21. Trudeau F, Péronnet F, Béliveau L, Brisson G. 6-OHDA sympathectomy and exercise performance in the rat. Arch Int Physiol Biochim. 1990;98:433-437.
22. Ungerer M, Hartmann F, Karoglan M, et al. Regional in vivo and in vitro characterization of autonomic innervation in cardiomyopathic human heart. Circulation. 1998;97:174-180.
23. 11C-Hydroxyephedrine as marker for neuronal catecholamine retention in reperfused canine myocardium. Coron Artery Dis. 1991;2:923-929.
24. Böhm M, La Rosée K, Schwinger RHG, Erdmann E. Evidence for reduction of norepinephrine uptake sites in the failing human heart. J Am Coll Cardiol. 1995;25:145-153.
25. Böhm M, Castellano M, Flesch M, et al. Chamber-specific alterations of norepinephrine uptake sites in cardiac hypertrophy. Hypertension. 1998;32:831-837.